- Inhibition of 6-phosphogluconate Dehydrogenase Reverses Cisplatin Resistance in Ovarian and Lung Cancer.
Inhibition of 6-phosphogluconate Dehydrogenase Reverses Cisplatin Resistance in Ovarian and Lung Cancer.
Frontiers in pharmacology (2017-07-18)
Wujian Zheng, Qi Feng, Jiao Liu, Yanke Guo, Lvfen Gao, Ruiman Li, Meng Xu, Guizhen Yan, Zhinan Yin, Shuai Zhang, Shuangping Liu, Changliang Shan
PMID28713273
ABSTRACT
Cisplatin (DDP) is currently one of the most commonly used chemotherapeutic drugs for treating ovarian and lung cancer. However, resistance to cisplatin is common and it often leads to therapy failure. In addition, the precise mechanism of cisplatin resistance is still in its infancy. In this study, we demonstrated that the oxidative pentose phosphate pathway enzyme 6-phosphogluconate dehydrogenase (6PGD) promotes cisplatin resistance. We showed that cisplatin-resistant cancer cells (C13